Claims
- 1. Compounds of the formula I ##STR6## wherein R.sup.1, R.sup.2 in each case independently of one another are H, A, OA, alkenyl, alkynyl, CR.sub.3 or Hal, where one of the radicals R.sup.1 or R.sup.2 is always .noteq.H,
- R.sup.1 and R.sup.2 together are also alkylene having 3-5 C atoms,
- R.sup.3, R.sup.4 in each case independently of one another are H, A, OA, NO.sub.2, NH.sub.2 NHA, NAA' or Hal,
- R.sup.3 and R.sup.4 together also are --O--CH.sub.2 --CH.sub.2 --, --O--CH.sub.2 --O-- or --O--CH.sub.2 --CH.sub.2 --O--,
- X is a 5- to 7-membered saturated heterocyclic ring which is mono- or disubstituted by R.sup.5, or a 5- to 7-membered unsaturated or saturated isocyclic ring which is mono- or disubstituted by R.sup.5,
- R.sup.5 is COOH, COOA, CONH.sub.2, CONAA', CONHA, CN, CH.sub.2 COOH or CH.sub.2 CH.sub.2 COOH,
- A,A' in each case independently of one another are H or alkyl having 1 to 6 C atoms,
- Hal is F, Cl, Br or I
- and
- n is 0, 1, 2 or 3,
- and physiologically acceptable salts thereof.
- 2. Compounds of the formula I according to claim 1
- (a) 4-[4-(3,4-methylenedioxy-benzylamino)-5,6,7,8-tetrahydro-[1]-benzothieno-[2,3-d]-pyrimidin-2-yl]-benzoic acid;
- (b) 4-[4-(3,4-methylenedioxybenzylamino)-6-methyl-thieno-[2,3-d]-pyrimidin-2-yl]-benzoic acid;
- (c) 4-[4-(3,4-methylenedioxy-benzylamino)-5,6-dimethyl-thieno-[2,3-d]-pyrimidin-2-yl]-benzoic acid;
- (d) 4-[4-(3,4-methylenedioxybenzylamino)-6-chloro-thieno-[2,3-d]-pyrimidin-2-yl]-benzoic acid;
- (e) 4-[4-(3-chloro-4-methoxy-benzylamino)-5,6,7,8-tetrahydro-[1]-benzothieno-[2,3-d]-pyrimidin-2-yl]-benzoic acid;
- (f) 1-[4-(3,4-methylenedioxy-benzylamino)-5,6,7,8-tetrahydro-[1]-benzothieno-[2,3-d]-pyrimidin-2-yl]-piperidine-4-carboxylic acid;
- (g) 1-[4-(3,4-methylenedioxy-benzylamino)-6-methyl-thieno-[2,3-d]-pyrimidin-2-yl]-piperidine-4-carboxylic acid;
- (h) 4-[4-(3,4-methylenedioxy-benzylamino)-5,6,7,8-tetrahydro-[1]-benzothieno-[2,3-d]-pyrimidin-2-yl]-cyclohexanecarboxylic acid;
- and physiologically acceptable salts thereof.
- 3. A process for the preparation
- a) of compounds of the formula I according to claim 1, and salts thereof, wherein X is a saturated 5- to 7-membered heterocyclic ring which is mono- or disubstituted by R.sup.5 and is bonded via N, characterized in that a compound of the formula II ##STR7## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and n have the meanings given and L is Cl, Br, OH, SCH.sub.3 or a reactive esterified OH group, is reacted with a saturated 5- to 7-membered heterocyclic ring which is mono- or disubstituted by R.sup.5, wherein R.sup.5 has the meaning given,
- or
- b) of compounds of the formula I according to claim 1, and salts thereof, wherein X is an unsaturated or saturated 5- to 7-membered isocyclic ring which is mono- or disubstituted by R.sup.5 and is bonded via C,
- characterized in that a compound of the formula III ##STR8## wherein R.sup.1, R.sup.2 and X have the meanings given
- and L is Cl, Br, OH, SCH.sub.3 or a reactive esterified OH group, is reacted with a compound of the formula IV ##STR9## wherein R.sup.3, R.sup.4 and n have the meanings given,
- or
- c) in a compound of the formula I, a radical R.sup.3 and/or R.sup.4 is converted into another radical R.sup.3 or R.sup.4 by reducing a nitro group, or a radical X is converted into another radical X by hydrolyzing an ester
- and/or in that an acid compound of the formula I is converted into one of its salts by treatment with a base.
- 4. Process for the preparation of pharmaceutical formulations, characterized in that a compound of the formula I according to claim 1 and/or one of its physiologically acceptable salts is brought into a suitable dosage form together with at least one solid, liquid or semi-liquid carrier or auxiliary.
- 5. Pharmaceutical formulation, characterized by a content of at least one compound of the formula I according to claim 1 and/or one of its physiologically acceptable salts.
- 6. A method for treating cardiovascular disease in a host in need thereof, comprising administering to said host an effective amount of a compound according to claim 1.
- 7. A method for treating erectile dysfunction in a host in a host in need thereof, comprising administering to said host an effective amount of a compound according to claim 1.
- 8. A method for inhibiting phosphodiesterase V activity, comprising administering an effective amount of a compound according to claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
196 44 228 |
Oct 1996 |
DEX |
|
Parent Case Info
This application is a 371 of PCT/EP97/05539, filed Oct. 8, 1997.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP97/05530 |
10/8/1997 |
|
|
6/11/1999 |
6/11/1999 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO98/17668 |
4/30/1998 |
|
|
US Referenced Citations (7)
Foreign Referenced Citations (7)
Number |
Date |
Country |
0 201 188 |
Dec 1986 |
EPX |
0 349 239 |
Jan 1990 |
EPX |
0 579 496 |
Jan 1994 |
EPX |
0 607 439 |
Jul 1994 |
EPX |
0 640 599 |
Mar 1995 |
EPX |
0 728 759 |
Aug 1996 |
EPX |
94 22858 |
Oct 1994 |
WOX |
Non-Patent Literature Citations (3)
Entry |
Lee et al. J. Med. Chem. 38, 3547-3557., 1995. |
Takase et al. J. Med. Chem. 37, 2106-2127, 1994. |
Takase et al. J. Med . Chem. 36, 3765-3770, 1993. |